These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1674669)

  • 1. Parkinson's disease: progress and controversies.
    Lee RG
    Can J Neurol Sci; 1991 Feb; 18(1):69. PubMed ID: 1674669
    [No Abstract]   [Full Text] [Related]  

  • 2. [Parkinson's disease].
    Yokochi M
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):5-14. PubMed ID: 10434578
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy of Parkinson's disease: are we at the end of the road?
    Nag D
    J Assoc Physicians India; 1992 Jun; 40(6):361-3. PubMed ID: 1360470
    [No Abstract]   [Full Text] [Related]  

  • 4. New approaches to Parkinson's.
    MacMahon D
    Practitioner; 1996 Dec; 240(1569):678-80, 682, 684. PubMed ID: 8995888
    [No Abstract]   [Full Text] [Related]  

  • 5. Factors influencing dopaminergic therapy of Parkinson's disease.
    Horowski R
    Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
    [No Abstract]   [Full Text] [Related]  

  • 6. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Parkinson's disease. Advances in the pharmacological therapy.
    Ghika J
    Eur Neurol; 1996; 36(6):396-9. PubMed ID: 8954312
    [No Abstract]   [Full Text] [Related]  

  • 8. [Use of dopamine analogs in Parkinson's disease treatment].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(12):53-5. PubMed ID: 12520782
    [No Abstract]   [Full Text] [Related]  

  • 9. Basal ganglia, Parkinson's disease and levodopa therapy. Proceedings of a meeting. St Thomas, Virgin Islands, January 2000.
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S1-126. PubMed ID: 11221749
    [No Abstract]   [Full Text] [Related]  

  • 10. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems.
    Carlsson A
    J Neural Transm (Vienna); 2002 May; 109(5-6):777-87. PubMed ID: 12111467
    [No Abstract]   [Full Text] [Related]  

  • 12. [Parkinson's disease. The parkinsonian patient treated with L. Dopa, the 30th anniversary of a new disease].
    Cambier J
    Presse Med; 1997 Sep; 26(28):1347-9. PubMed ID: 9365495
    [No Abstract]   [Full Text] [Related]  

  • 13. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
    Riederer P; Gerlach M; Müller T; Reichmann H
    Parkinsonism Relat Disord; 2007 Dec; 13(8):466-79. PubMed ID: 17919963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenic substances in Parkinson disease and new therapeutics considering the etiologic mechanism].
    Nagatsu T
    Nihon Rinsho; 1988 Sep; 46(9):2086-97. PubMed ID: 2907356
    [No Abstract]   [Full Text] [Related]  

  • 15. Ropinirole (SK and F 101468) in the treatment of Parkinson's disease.
    Kleedorfer B; Stern GM; Lees AJ; Bottomley JM; Sree-Haran N
    J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):938. PubMed ID: 1683897
    [No Abstract]   [Full Text] [Related]  

  • 16. Update on the management of Parkinson's disease.
    Standaert DG; Stern MB
    Med Clin North Am; 1993 Jan; 77(1):169-83. PubMed ID: 8093493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parkinson's disease].
    Mizuno Y
    No To Shinkei; 1994 Mar; 46(3):217-27. PubMed ID: 7910751
    [No Abstract]   [Full Text] [Related]  

  • 18. Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 1993 Apr; 35(894):31-4. PubMed ID: 8096322
    [No Abstract]   [Full Text] [Related]  

  • 19. Deep-brain stimulation for Parkinson's disease.
    Hou B; Jiang T; Liu R
    N Engl J Med; 2010 Sep; 363(10):987-8; author reply 988. PubMed ID: 20830819
    [No Abstract]   [Full Text] [Related]  

  • 20. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.